Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 161

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 161
---
 resources and could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or growth prospects. We may not be able to protect or enforce our intellectual property rights throughout the world. We have not yet registered certain of our trademarks in all of our potential markets. Future patents may not be registered in all potential markets at the same time. Filing, prosecuting and defending patents on our products and services in all countries would be expensive and difficult due to varying laws protecting intellectual property rights. Consequently, we may encounter difficulties in protecting and defending such rights in foreign jurisdictions, and our competitors may use technologies in countries where we have not obtained patent protection. Additionally, trademark registration is required to enforce trademark rights in certain countries, and proceedings to enforce patent rights in foreign jurisdictions could be costly and time -consuming. Changes in the law and legal decisions by courts in foreign countries may also affect the ability to obtain adequate protection for technology and the enforcement of intellectual property. Companies must ultimately seek patent protection on a country -by -countrybasis, which is an expensive and uncertain process. In some countries, patents may provide limited or no benefit, and the legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. We may be unable to obtain sufficiently broad protection, or we may lose patent protection. As patent prosecution of biotechnology and pharmaceutical companies is highly uncertain, involves complex legal and factual questions, and has been the subject of litigation in recent years, the issuance, scope, validity, enforceability and commercial value of any future patent rights are highly uncertain. Our future patent applications may not result in granted patents that protect our drugs or technologies which would render us unable to prevent others from commercializing competitive drugs or technologies. The coverage of patent claims may be significantly reduced during patent prosecution before the patent is granted and the scope can also be reinterpreted after grant, which may not provide us meaningful protection, may not allow us to exclude competitors or may not provide us with any competitive advantage. We may not be able to protect and enforce our trademarks. Currently, we have a broad and diversified portfolio of trademarks, which represents a valuable asset for our company. Certain of our